To effectively manage increased patient volumes and financial demands, healthcare organizations are adopting solutions for electronic patient records and systems that allow them to share patient information in real-time. This segment of e-health is growing, and the growth is expected to accelerate in the coming years. Ortivus is well-positioned to capitalize on this development.

Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.

 Stock SymbolISINShares OutstandingVotes/shareTotal Number of Votes
Class AORTI ASE00001889301,662,6821016,626,820
Class BORTI BSE000012308542,644,786 142,644,786

The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,807,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.

 

Ortivus A

Ortivus B

Hover the mouse over the graphs to see the share price at the corresponding date.

 

Top 10 Shareholders

 Share of Capital
PONDERUS INVEST AB25.8%
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION6.8%
NORDNET PENSIONSFÖRSÄKRING AB6.8%
PETTERSSON, RUNE6.3%
FRAIM, ING-MARIE4.4%
RASPART FÖRVALTNING AB4.2%
SELIGSON & CO PHOENIX FUND3.9%
ERIKSSON, NILS-ARNE3.5%
ADOLFSSON, PÄR-OLA3.2%
GAGAB AB1.9%
Sum of top 10 shareholders66.83%

Ortivus top 10 shareholders as per the 30th of September 2019. As per the 30th of September 2019 Ortivus had 5,472 shareholders.

Subscribe to Financial Information 

  • Interim report Q3 2019: 25/10/2019, 8.30 am
  • Year-end report Q4 2019: 13/02/2020, 8.30 am
  • Annual report 2019: 18/03/2020
  • Interim Report Q1 2020: 23/04/2020, 8.30 am
PREVIOUS AG MEETINGS
Interim report Ortivus AB (publ) for the period Januari – September 2019
ORTIVUS BUILD ORDER STOCK FOR FUTURE DELIVERIES
Read more
Ortivus has received an order to equip new vehicles that SCAS are procuring with new ePCR devices for MobiMed
South Central Ambulance Service, SCAS, in the UK has placed an order for 54 tablets
Read more
ORTIVUS SIGN CONTRACT WITH ST ENGINEERING’S ELECTRONICS SECTOR TO ADVANCE PRE-HOSPITAL SOFTWARE IN SINGAPORE
Ortivus continues to expand internationally and deliver value to the medical records system in Singapore
Read more
ORTIVUS HAS BEEN SELECTED AS PREFERRED BIDDER FOR PREHOSPITAL CARE BY THE SOUTH WESTERN AMBULANCE SERVICE TRUST (SWAST)
Ortivus has been selected as the preferred bidder to deliver its prehospital MobiMed electronic patient
Read more
Ortivus agreement with Northern Ireland Ambulance Service HSC Trust on ambulance records now signed
Ortivus, as previously announced (March 22nd, 2019), has been awarded a contract for the delivery
Read more
Finansinspektionen: Flaggningsmeddelande i Ortivus Aktiebolag
Flaggningsmeddelande i Ortivus Aktiebolag Anmälan om förvärv eller överlåtelse av finansiella instrument. Emittent 556259-1205 Ortivus
Read more
Reidar Gårdebäck utsedd till ny vd för Ortivus
Styrelsen för Ortivus AB har beslutat utse Reidar Gårdebäck till ny verkställande direktör för Ortivus
Read more
Ortivus AB (publ) (“Ortivus”) genomför en riktad nyemission- tillförs 15 MSEK
Styrelsen för Ortivus AB (publ) har med stöd av bemyndigande från årsstämman 2019 beslutat om
Read more
all Press releases

The board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations.

(Documents below are in Swedish only)

  1. Fullmaktsblankett
  2. Styrelseprotokoll
  3. Redogörelse av styrelsen enligt ABL 13-6
  4. Kallelse
  5. Revisorsyttrande
  6. Protokoll extra bolagsstämma i Ortivus

The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations.

Download the prospectus (in Swedish) “Ortivus-AB-(publ)_Prospekt-avseende-upptagande-till-handel-av-nyemitterade-aktier_2019-07-10” here.